Tariff trade war could raise medical costs — but not quite yet
A brewing trade war between the U.S., China, Canada and Mexico could increase the cost of medical supplies, intensify drug shortages and limit device makers' ability to import critical supplies.
The full scope of tariff impacts will take some time to completely take shape, and Accreditation Council for Medical Affairs founder and CEO William Soliman tells NewsNation that prices and future drug availability are difficult to predict.
Ontario premier: Trump tariffs 'backfired,' inflation to hit US
'A lot of the common drugs that Americans take — your cholesterol lowering drugs, your blood thinners, your antibiotics — a lot of these drugs, a lot of their active pharmaceutical ingredients, are made in China. They're made in Canada,' Soliman said.
'You are going to see, potentially, price issues in terms of price increases and maybe potentially shortages of those generic drugs in the U.S.,' he added.
About 90% of the drugs Americans consume are generic — of that percentage, a vast majority are at least partly manufactured overseas.
What is causing your spring allergies and what can you do to prevent them?
That includes common drugs like antibiotic Z-Pak, anticoagulant Coumadin and cancer-fighting drugs.
But Soliman said patients shouldn't panic just yet. There's likely a 12- to 18-month stockpile for many drugs, he said, so there should be no immediate issue with supply chain shortages when it comes to generic medications.
Name-brand drugs, however, could see significant problems when it comes to availability in the future, Soliman said.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
40 minutes ago
- Forbes
Care Without Distance: Rural Health's Leap Into The Digital Age
The rising cost of delivering care to rural Americans is only one part of the story. What matters most to patients, and to those of us who have spent our careers caring for them, is getting care when and where it's needed, in the most convenient (and yes, affordable) way possible. When I was practicing surgery as a heart specialist, many of my patients came from small towns. They were referred from rural clinics that were doing their best, often without resources or specialist support. I saw firsthand how delays in diagnosis or distance from care could change the course of an illness. These experiences stay with me. They are part of why I believe so strongly that we can and must build a better, more connected system for rural America. This moment in time, I believe, brings both hope and genuine opportunity. With the right strategy and newly available technologies, we can deliver care that is closer to home, more consistent, and more personal. Daily advances in artificial intelligence (AI), digital health, and virtual care are opening the doors to revolutionary new ways to connect patients to care. These methods are already transforming delivery in other parts of the country and the world. In July 2025, Congress passed the One Big Beautiful Bill Act which includes the Rural Health Transformation Program, an innovative $50 billion federal initiative to support rural communities to be disproportionately impacted by the Act's Medicaid spending cuts and other reimbursement reductions. Beginning in 2026, the Centers for Medicare & Medicaid Services (CMS) will allocate $10 billion annually through 2030 to states that submit qualifying transformation plans. These funds will support high-priority initiatives such as broadband expansion, digital infrastructure, chronic disease management, and training for the adoption of technologies such as AI and remote patient monitoring. Though limited in size and scope, the Transformation Program represents a meaningful down payment on a more modern and equitable rural health sector. It's more than a funding package; it reflects a growing recognition in Washington that transformative technology, especially AI, must play a central role in the future of rural health. In Part Two of this series, we documented the impact of rural hospital closures. But we don't need to rebuild what was lost brick by brick. We can build something better: care that moves to and with the patient, not just inside a building. And rural communities, with their strong culture of self-reliance, adaptability, resilience, and strong local ties, are uniquely positioned to benefit from and potentially lead this transformation. Barriers to Access—and Why They Must Be Overcome Rural America is home to 60 million people, nearly one in five Americans. Yet these communities experience some of the worst health outcomes in the country. Chronic illnesses are more common. Life expectancy is shorter. And getting timely, high-quality care is harder than ever. On average, rural Americans live twice as far from the nearest hospital as their urban or suburban peers. That distance is growing as more rural hospitals and clinics close, many operating on razor-thin margins with aging infrastructure and too few clinicians to sustain services. As discussed in Part One, these facilities are more than care sites. They are employers, civic institutions, and sources of community trust. When one closes, the effects ripple out. A single hospital closure can lead to a 14% decline in employment in the county it served. Fewer young doctors are choosing to practice in rural communities. Medical specialists are nearly nine times more concentrated in urban areas than rural ones. The provider shortage is worsening just as demand for care, especially for chronic conditions and behavioral health, is growing. To break this cycle, we need to reimagine how care is delivered. That means shifting away from the narrow model of centralized, inpatient facility care and toward more connected outpatient and community-based systems, including mobile care, telehealth, and in-home services. But to get there, we must invest in the infrastructure that will make this possible. That's where modern technology, and AI in particular, can play a transformational role. Laying the Groundwork for a Digital Rural Health System Before rural communities can fully benefit from artificial intelligence and other cutting-edge technologies, they need the right foundation. And today, that foundation is uneven at best. Many rural hospitals and clinics rely on outdated electronic medical records that can't share data or integrate with newer tools. Only about 64% of rural physicians use certified electronic health record systems. Twenty-two percent of rural households lack access to high-speed broadband. Most small, independent hospitals can't afford to have dedicated IT or cybersecurity staff. And while AI is becoming a more common feature in many industries, fewer than 1% of rural Americans feel confident using it in the workplace, though the majority say they want to learn. These gaps matter. Because if we don't address them now, rural America risks falling even further behind as digital care models increasingly become the norm. What's needed is clear: Some organizations are already taking action. Thrive Health Tech*, a company we helped incubate at Frist Cressey Ventures, equips patients with mobile devices that connect to a HIPAA-compliant wireless network, helping bridge the broadband gap in hard-to-reach communities. Major technology companies are beginning to partner with rural hospitals to modernize their cybersecurity systems and digital infrastructure. But scaling these solutions takes more than innovation alone. It will require new commitments to public-private partnerships with policy alignment and sustained investment. That's what makes the Rural Health Transformation Program so interesting. With $10 billion in federal funding each year between 2026 and 2030, the program gives states the opportunity and the incentive to build the appropriate infrastructure that rural health requires to thrive in the digital age. From Potential to Practice: How AI Is Already Advancing Rural Health Advancements in multi-modal language models, reasoning models, and voice agents are central to this innovation. Investments in frontier models and technical ingenuity of engineers are producing tools that are changing care delivery for the better. These are the building blocks for the hospitals and clinics of the future. Once the foundation is laid, rural communities are positioned to move from planning to action. Across the country AI tools are already being deployed to support patients, reduce administrative burdens, and enhance how clinicians deliver care. These tools are not theoretical. We know they work, and they are especially well-suited to the needs of rural populations, where distance and access are larger barriers to health. At Frist Cressey Ventures, we sit at the front line of technology innovation in healthcare. Through deep relationships with founders, health systems, medical groups, and independent physicians, we see the impact that AI applications are having on patient outcomes, clinician satisfaction, and operational efficiency at sites of care. For illustration purposes, here are some of what we are seeing in rural health today: AI-enabled platforms are enhancing how patients understand and manage their own health. Large language models can deliver personalized education, explain care plans in everyday language, and do so in multiple languages and literacy levels by text or voice. When paired with remote monitoring, this creates a continuous, real-time link between patients and their care teams. In places where behavioral health access is limited, AI-powered applications have been shown to be highly effective in providing structured talk therapy and supporting people burdened with social isolation, depression, or chronic illness. One compelling example of reaching rural communities is Sprinter Health, which deploys trained clinical staff to patients' homes in rural areas like Kentucky, Maine, and Louisiana. Using a custom logistics platform powered by AI, Sprinter aligns clinician travel with outreach needs, creating efficient, high-density routes, even in the most remote zip codes. These visits, often funded by health plans and paired with remote nurse practitioner consults, reconnect patients with care on their own schedules, reducing barriers and improving outcomes. Clinicians in rural America are asked to do more with less. AI tools help them reclaim time for what matters most: patient care. Voice-enabled documentation, automated coding, and streamlined prior authorizations reduce the suffocating administrative burden while improving billing accuracy and compliance. These tools also reduce physician and nursing burnout. One example: Ambience Healthcare* provides a suite of AI tools, including AI-enabled 'ambient scribes' with an integrated coding and compliance engine that have led to a 40% decrease in documentation time. Some health systems have reported revenue increases of $13,000 per physician annually by using these tools. AI is also helping rural clinics and hospitals improve their back office, automating scheduling, eligibility checks, and insurance workflows. Language models are flagging coding errors, demystifying payer rules, and reducing costly denials. These improvements aren't flashy, but they're critical to keeping rural providers financially solvent. An example is CodaMetrix*, which has shown a 70% reduction in manual coding work and a 60% drop in coding-related denials using digital automation and AI tools. AI is also bridging the specialist gap. Advanced clinical reasoning models are being used to supplement rural clinicians' decision-making, offering diagnostic recommendations when specialists aren't available. In radiology, large vision models can review and triage imaging studies, highlighting urgent cases for rapid interpretation. In Kenya, OpenAI's partnership with primary care provider Penda Health, though in a different setting, has shown what's possible: a 16% reduction in diagnostic errors over 40,000 patient visits. This kind of augmentation won't replace local physicians. It will support and extend their reach, ensuring that rural patients, who by geography are typically more physically distant from their providers, receive the same standard of care as those in more urban centers. Governance and Guardrails: Making AI Safe, Trusted, and Transparent While the promise of AI in rural health is real, we must proceed thoughtfully. The speed of innovation cannot come at the expense of safety, patient trust, or clinical integrity. And in rural settings, where resources are stretched and IT support may be more limited, clear guardrails are essential. AI tools must be explainable. They must be tested for bias. They must work consistently across diverse populations and care settings. And they must be monitored in real time so that rural hospitals and clinics know exactly how these systems are performing. Importantly, technology exists today to make this possible, even for rural independent facilities outside larger, more resource-complete systems. Companies like Qualified Health* are building platforms that allow rural providers to implement AI safely and smartly. Their systems provide audit trails, performance dashboards, and governance frameworks that give local teams control as well as convenience and safety. Technology alone won't change rural health. But technology implemented wisely with strong community buy-in and a commitment to safety can. And rural communities, free of many oftentimes restraining legacy systems, may well be the best situated to lead. We've seen it before in other fields. In parts of Africa and India, mobile phones bypassed traditional landline infrastructure altogether. In China, electric vehicle adoption accelerated because the country leapt directly into the next generation of mobility. Rural America has the same potential when it comes to health. Indeed, rural providers can leapfrog older models and become national leaders in delivering smarter, more equitable care. A Future Within Reach Rural health is not failing. It is changing. Yes, many inpatient hospitals are struggling, and recent Congressional action in reimbursement and Medicaid cuts make the environment more challenging. Many have closed, and many feel that the recent reconciliation law will lead to the demise of others. But this does not have to be an end of care in rural America. In fact, it opens the door to something better, built for today and for tomorrow. A system more responsive, more connected, and more sustainable than what came before. The Rural Health Transformation Program is not a silver bullet. It is limited in size, and it cannot address every challenge rural providers face. But it does point in the right direction. It signals that rural health care matters, and that technology, wisely applied, can help power a system that works better and more sustainably for patients, caregivers, and communities. This isn't just about modernizing infrastructure. It's about honoring the values that make rural America such a powerful place to lead this change. In rural communities, people take pride in self-reliance and resourcefulness. They know how to figure things out. They trust neighbors more than distant systems. They solve problems without waiting for someone else to do it. And they've long practiced the kind of resilience that will be needed to adapt, lead, and thrive in a new model of care. That new model won't rely on size. It will rely on connection. It will deliver care not just in hospitals, but in homes, local clinics, and mobile units. With the right technology in place, rural providers can leapfrog outdated systems and become national leaders in delivering smarter, earlier, and more personal care. Rural America has always led in farming, in military service, in faith and family. It can lead in health care, too. That's what this moment offers. Not a return to the past, but a chance to shape the future. A future defined by innovation, partnerships, connection, and Cressey Ventures, of which the author is a partner, has a minority investment in the companies marked with an asterisk above. They are for illustrative purposes only.
CNBC
an hour ago
- CNBC
Eli Lilly hikes price of diabetes drug Mounjaro in UK as Trump pressures pharma to align drug costs
Eli Lilly on Thursday said it is raising the list price of its blockbuster diabetes drug Mounjaro in the U.K. starting in September, as President Donald Trump pressures drugmakers to lower U.S. drug prices and hike them abroad. In a statement, Eli Lilly said it reached an agreement with the U.K. government to increase the list price of the weekly injection, while "maintaining access" for patients covered under the publicly funded health-care system, the National Health Service, or NHS. Eli Lilly told CNBC that the price hike will not affect the drug's availability under NHS, and it wants to work with the government to boost access. The company added that it does not determine prices that private health-care providers set, but is working with them to ensure access to Mounjaro. In a statement on Thursday, NHS said Mounjaro's list price increase "will not affect NHS commissioning of tirzepatide in England for eligible people living with obesity, based on clinical priority, or as a treatment for type 2 diabetes." Tirzepatide is the active ingredient in Mounjaro and its counterpart for weight loss, Zepbound. Mounjaro's current list price in the UK ranges from £92 (about $124.89) to £122 a month, depending on the dose size, according to Eli Lilly. The drug's new list price will increase to between £133 and £330 starting on Sept. 1. The company added that it is working with certain governments and expects to make pricing adjustments in those countries by that date. In the U.S., the list price for a month's supply of Mounjaro is $1,079.77 before insurance and other rebates. Eli Lilly said it supports the Trump administration's goal of keeping the U.S. the "world's leading destination for biopharmaceutical research and manufacturing, and the objective of more fairly sharing the costs of breakthrough medical research across developed countries." "This rebalancing may be difficult, but it means the prices for medicines paid by governments and health systems need to increase in other developed markets like Europe in order to make them lower in the US," the company said in the statement. The announcement comes after Trump in July sent separate letters to 17 drugmakers, including Eli Lilly, calling on them to take steps to lower drug prices by Sept. 29. The move built on the president's executive order in May reviving a controversial plan – the "most favored nation" policy – that aims to slash drug costs by tying the prices of some medicines in the U.S. to the significantly lower ones abroad. U.S. prescription drug prices are two-to-three times higher on average than those in other developed nations – and up to 10 times more than in certain countries, according to the Rand Corp., a public policy think tank. Trump has said he wants to narrow that gap to stop Americans from being "ripped off." Eli Lilly's announcement on Thursday comes as the industry braces for Trump's planned tariffs on pharmaceuticals imported into the U.S. In its statement, the company said it opposes those tariffs, arguing they will "raise costs, limit patient access, and undermine American leadership, especially for companies already investing heavily in domestic manufacturing." In recent months, Eli Lilly was among several drugmakers to announce new plans to invest in U.S. manufacturing sites.
Yahoo
2 hours ago
- Yahoo
Lilly raises UK obesity shot price as Trump pressures pharma
(Bloomberg) — Eli Lilly & Co. is raising the list price for its obesity shot in the UK by as much as 170%, as the pharma industry comes under pressure from US President Donald Trump to increase medicine prices in Europe and lower them for Americans. The current list price in the UK for Lilly's Mounjaro ranges from £92 ($124.89) to £122 a month, depending on the dose. This will increase to between £133 and £330 from Sept. 1, with the US drugmaker saying it aims to bring rates in line with other countries. Trump sent letters to 17 of the world's largest drugmakers earlier this month, including Lilly and Novo Nordisk A/S, which makes the competing shot Wegovy, insisting they lower what they charge Medicaid in the US for existing drugs. He gave the companies 60 days to comply, saying he wants companies to negotiate harder with 'foreign freeloading nations' who pay less for their medicines. Lilly said the increase follows a review that looked to address pricing inconsistencies. The UK was one of the first countries where Mounjaro was introduced, with rates 'significantly below the European average to prevent delays' in availability via the National Health Service, the company added. 'With changes in the environment and new clinical evidence supporting the value of Mounjaro, Lilly are now aligning the list price more consistently to ensure fair global contributions to the cost of innovation,' it said. Affordability Concerns The new list price is still well below the level in the US, where it costs over $1,000 a month. Still, the higher prices raised concerns in online forums from patients who say the drug will be unaffordable for them. Patients in the UK usually get most medicines on the National Health Service for a set prescription price of £9.90. However, obesity drugs have only just started to be rolled out on the NHS and the criteria for access are stringent. So far, the majority of patients who access the weight-loss shots have been doing so privately. The actual price that these patients pay is likely to be well below the list price, because Lilly negotiated commercial agreements with private providers. Still, those providers are likely to face difficult decisions on how much to pass on any price increase to patients. Pharmacies like Walgreens Boots Alliance Inc.'s Boots and Superdrug, as well as online providers like Juniper and Voy that have focused on weight-loss drugs, have benefited from the rush for obesity shots. If patients are unable to afford more expensive Mounjaro, they may also switch to Novo's Wegovy. Novo has not yet announced a similar increase in price for its obesity drug. While the list price has increased, Lilly said it is working with private providers to maintain access for patients. Separately, the company reached an agreement with the NHS to ensure continued supply and patient access. —With assistance from Madison Muller. (Updates with more detail on pharmacies selling the shots, from paragraph nine) ©2025 Bloomberg L.P. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
